by Josh Jardine THECRIMSONRIBBON / GETTY IMAGES
There was a great deal of celebrating in certain circles on Monday, when British pharmaceutical giant GW Pharmaceuticals announced that it had received FDA approval for Epidiolex, which is derived from cannabis and is used to treat two rare forms of pediatric epilepsy, Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). SeekingAlpha reports that children suffering from both kinds of epilepsy who treated with Epidiolex showed reduced seizures wh
There was a great deal of celebrating in certain circles on Monday, when British pharmaceutical giant GW Pharmaceuticals announced that it had received FDA approval for Epidiolex, which is derived from cannabis and is used to treat two rare forms of pediatric epilepsy, Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). SeekingAlpha reports that children suffering from both kinds of epilepsy who treated with Epidiolex showed reduced seizures wh
